BioLargo Expands Federal Reach with Breakthrough Medical Solution for Veterans
Westminster, Thursday, 3 September 2026.
BioLargo’s subsidiary Clyra Medical partnered with Spartan Medical to supply federal healthcare facilities with ViaCLYR, a wound solution clinically proven to eliminate 99.9999% of pathogens in 60 seconds.
BioLargo Expands Federal Reach
BioLargo, Inc. (OTC: BLGO) announced on September 3, 2026, that its subsidiary Clyra Medical Technologies has entered a strategic agreement with Spartan Medical [1][2]. This partnership establishes a new distribution channel specifically targeting the United States government healthcare market [1]. The agreement supplements Clyra Medical’s existing commercial distribution network and international presence across 18 countries [1][2].
Product Rollout Acceleration
The collaboration aims to accelerate the commercial rollout of the ViaCLYR™ wound irrigation solution [1]. ViaCLYR™ is an FDA 510(k)-cleared product designed for cleansing, irrigating, and debriding various wound types [2]. These wounds include burns, pressure ulcers, and diabetic or stasis ulcers [2].
Federal Market Access and ECAT Listing
Through this agreement, ViaCLYR™ gains access to Department of Veterans Affairs and Department of Defense facilities [1]. The product has been added to the Defense Logistics Agency Electronic Catalog (ECAT) as of early September 2026 [1][2]. This listing enables immediate resale to federal agency healthcare providers [1].
Eligible Facilities and Contractor Status
Eligible facilities for procurement include the Federal Bureau of Prisons and the Indian Health Service [2]. Civilian hospitals operating under VA Community Care contracts are also included in the distribution scope [2]. Spartan Medical serves as a veteran-owned-and-operated government contractor facilitating this access [2].
Clinical Performance and Technology
ViaCLYR™ utilizes the Clyrasept™ Copper-Iodine Complex Solution (CICS) [1]. In clinical testing, the solution eliminated 99.9999% of 18 pathogens within 60 seconds [1][2]. The product provides 72-hour persistent antimicrobial management without the need for rinsing [1].
Efficacy and Care Standards
The technology addresses infection control without requiring repeated reapplication [2]. It is noted as non-cytotoxic in clinical assessments [2]. This performance profile supports its positioning as a standard of care across government healthcare continuums [2].
Strategic Growth and 2027 Outlook
BioLargo anticipates a national launch of a new surgical product in 2027 [1]. The company is currently scaling manufacturing capacity in preparation for this launch [1]. Dennis Calvert, CEO of BioLargo, stated the agreement strengthens Clyra’s commercial rollout and supports revenue growth [1].
Executive Commentary on Partnership
Steve Harrison, Chief Executive Officer of Clyra Medical Technologies, expressed confidence that ViaCLYR™ will become the standard of care across VA and Military facilities [2]. Vince Proffitt, President of Spartan Medical, described the solution as game-changing for facilities they serve [1]. The partnership demonstrates a commitment to improving care for veterans and service members [1][2].